AU Patent

AU2003221684A1 — Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor

Assigned to SmithKline Beecham Corp · Expires 2003-10-27 · 23y expired

What this patent protects

Patent listed against lapatinib-ditosylate.

Drugs covered by this patent

lapatinib-ditosylate (LAPATINIB DITOSYLATE)

Patent Metadata

Patent number: AU2003221684A1
Jurisdiction: AU
Classification: —
Expires: 2003-10-27
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.